Ultragenyx Announces Patent License Agreement with UniQuest for Treatment of Epilepsy and Other Seizure-Related Disorders

Ultragenyx Pharmaceutical Inc., a bio-pharmaceutical company focused on the development of novel products for rare and ultra-rare diseases announced patent license agreement with UniQuest Pty Ltd. According to the agreement, Ultragenyx will provide treatment of refractory epilepsy and other seizure-related and neurologic disorders with Triheptanoin (UX007).


For more details, click here.


Kameshwar Eranki is CEO of VajraSoft Inc. He is author of the eBooks – Managing Innovations for Profitable growth and The Definitive Guide of Patent Life Cycle Management. For free download of the eBooks, click download Free eBook or click download Free eBook – PLM.